Ebihara Y, Miyamoto M, Shichinohe T, Kawarada Y, Cho Y, Fukunaga A, Murakami S, Uehara H, Kaneko H, Hashimoto H, Murakami Y, Itoh T, Okushiba S, Kondo S, Katoh H
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
Dis Esophagus. 2004;17(2):150-4. doi: 10.1111/j.1442-2050.2004.00393.x.
The transcription factor E2F-1, a downstream regulator of the p16-cyclinD-Rb pathway, is required for cell cycle progression. Evidence shows that overexpression of E2F-1 can either promote or inhibit the development of tumors, depending on tissue or experimental conditions. However, the clinical impact of E2F-1 expression on esophageal squamous cell carcinoma (ESCC) remains unknown. To analyze E2F-1 expression in ESCC, we investigated the immunoreactivity of E2F-1 and its correlation with clinicopathological features in 122 patients who underwent surgical resection for ESCC. Positive E2F-1 immunostaining was detected in 73 patients (59.8%). Positive E2F-1 immunostaining correlated positively with pathologic stage (P = 0.0103), p-Grade (P = 0.0014) and pT (P = 0.0192). The overall survival rate was worse in patients with E2F-1-positive tumors than in patients with E2F-1-negative tumors (P = 0.0290). Over-expression of E2F-1 is associated with tumor progression and a worse prognosis after surgery in ESCC.
转录因子E2F-1是p16-细胞周期蛋白D-Rb通路的下游调节因子，是细胞周期进程所必需的。有证据表明，E2F-1的过表达可促进或抑制肿瘤发展，这取决于组织或实验条件。然而，E2F-1表达对食管鳞状细胞癌（ESCC）的临床影响仍不清楚。为了分析ESCC中E2F-1的表达情况，我们调查了122例行ESCC手术切除患者的E2F-1免疫反应性及其与临床病理特征的相关性。73例患者（59.8%）检测到E2F-1免疫染色阳性。E2F-1免疫染色阳性与病理分期（P = 0.0103）、p分级（P = 0.0014）和pT（P = 0.0192）呈正相关。E2F-1阳性肿瘤患者的总生存率低于E2F-1阴性肿瘤患者（P = 0.0290）。E2F-1的过表达与ESCC的肿瘤进展和术后较差的预后相关。
Zotero 插件